In analyses stratified by HPV 16E6/18E6 and EGFR expression (E6−tEGFR−, E6+tEGFR− or E6−tEGFR+, and E6+tEGFR+), we found that lung adenocarcinoma patients with E6+tEGFR+ had the longest survival time (overall p = 0.055, median = 66 months; E6+tEGFR+ vs. E6−tEGFR−, HR [95% CI] = 0.77 [0.62−0.96], p = 0.019). The gene discussed is EGFR; the disease is lung adenocarcinoma.